2025-05-21-Jefferies-赢创（EVK）_赢创公司CMD_-初步解读_7页_206kb

报告摘要

Evonik CMD Summary

Core Content

Evonik Industries AG has introduced new medium-term financial targets for the period up to FY27F. These targets are designed to reflect the company's strategic direction and financial performance expectations, with a focus on improving profitability, cash generation, and shareholder returns.

Key Financial Targets

EBITDA Growth: Targeting an increase of +€1bn in EBITDA by FY27F, compared to FY23. This growth is supported by €500mn in cost reductions and €500mn in organic growth.
EBITDA Margin: Aiming for margins in the range of 18-20%, up from the previous 13.6%.
Cash Conversion Ratio: Targeting a sustained ratio of >40%, which is already a key performance indicator for the company.
ROCE: Expected to reach ~11%, which is well above the cost of capital. This is an improvement from the FY24 ROCE of 7.1%.
Dividend Policy: A reliable and sustainably growing dividend is a priority, with a FY24A dividend of €1.17.

Financial Projections for FY25-27F

Operating Cash Flow: Targeted at ~€5.5bn.
Capex: Estimated at €2.7bn, with annual capital expenditures in the range of €850-900mn.
Free Cash Flow (FCF): Projected to be ~€2.8bn over the period, providing ample capacity for dividend payments and deleveraging.

Regional Sales Share

Evonik aims to balance its sales across regions:

Americas: Targeting ~30% of total sales.
EMEA: Targeting ~45% of total sales.
Asia-Pacific: Targeting ~25% of total sales.

This structure is intended to ensure a diversified revenue base and reduce reliance on any single region.

Divisional Structure Insights

Evonik has restructured into two main divisions: Custom Solutions and Advanced Technologies.

Advanced Technologies:
- Has an average EBITDA margin of 18.3% over six years.
- Margins are more volatile, with a trough of 12.6% and a peak of 21.3%.
- Methionine price volatility is a key driver of margin fluctuations, representing ~1/3 of segment earnings.
- ROCE is also more volatile, ranging from mid-single digit to double-digit levels.
Custom Solutions:
- Margin volatility is still relatively high (~500bps peak to trough).
- Segment ROCE averages ~10% over the last six years.
- Top line growth has averaged ~5% annually, but EBITDA has been flat, indicating the need for improved performance in this segment.

Investment Recommendation

Rating: UNDERPERFORM
Price Target: €18.80, which is -7% below the current price of €20.30.
Market Cap: €9.5B (€10.7B in USD).
Float: 49.0% (24.83 million shares in USD).

Valuation Methodology

Jefferies uses multiple methodologies to determine price targets, including:

Discounted Cash Flow (DCF)
EBITDA and EPS analysis
Free Cash Flow (FCF)
EV/EBITDA and P/E ratios
Sum of the parts and net asset value
Dividend returns and Return on Equity (ROE)

Analyst Disclosures and Conflicts of Interest

Jefferies has a potential conflict of interest due to its business relationships with companies covered in its research. This may affect the objectivity of the reports, and investors are advised to consider this report as one of many factors in their investment decisions.

Investment Risks

Methionine Prices: A significant factor affecting EBITDA and margin volatility.
End-Market Demand: Uncertainty in demand for segments like Smart Materials and Specialty Additives.
Currency Risk: Exchange rate fluctuations may impact returns for non-US investors.
Regulatory and Legal Restrictions: Vary by region and may affect the distribution and use of the report.

Other Important Disclosures

This report is intended for professional or institutional investors in certain jurisdictions.
It is not tailored to individual investors and does not constitute investment advice.
Jefferies does not guarantee the accuracy or completeness of the information provided.
The report may contain forward-looking statements subject to risks and uncertainties.